Cargando…
Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies
The anatomical differences between the retinas of humans and most animal models pose a challenge for testing novel therapies. Nonhuman primate (NHP) retina is anatomically closest to the human retina. However, there is a lack of relevant NHP models of retinal degeneration (RD) suitable for preclinic...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396314/ https://www.ncbi.nlm.nih.gov/pubmed/37531424 http://dx.doi.org/10.1126/sciadv.adg8163 |
_version_ | 1785083733440724992 |
---|---|
author | Ail, Divya Nava, Diane Hwang, In Pyo Brazhnikova, Elena Nouvel-Jaillard, Céline Dentel, Alexandre Joffrois, Corentin Rousseau, Lionel Dégardin, Julie Bertin, Stephane Sahel, José-Alain Goureau, Olivier Picaud, Serge Dalkara, Deniz |
author_facet | Ail, Divya Nava, Diane Hwang, In Pyo Brazhnikova, Elena Nouvel-Jaillard, Céline Dentel, Alexandre Joffrois, Corentin Rousseau, Lionel Dégardin, Julie Bertin, Stephane Sahel, José-Alain Goureau, Olivier Picaud, Serge Dalkara, Deniz |
author_sort | Ail, Divya |
collection | PubMed |
description | The anatomical differences between the retinas of humans and most animal models pose a challenge for testing novel therapies. Nonhuman primate (NHP) retina is anatomically closest to the human retina. However, there is a lack of relevant NHP models of retinal degeneration (RD) suitable for preclinical studies. To address this unmet need, we generated three distinct inducible cynomolgus macaque models of RD. We developed two genetically targeted strategies using optogenetics and CRISPR-Cas9 to ablate rods and mimic rod-cone dystrophy. In addition, we created an acute model by physical separation of the photoreceptors and retinal pigment epithelium using a polymer patch. Among the three models, the CRISPR-Cas9–based approach was the most advantageous model in view of recapitulating disease-specific features and its ease of implementation. The acute model, however, resulted in the fastest degeneration, making it the most relevant model for testing end-stage vision restoration therapies such as stem cell transplantation. |
format | Online Article Text |
id | pubmed-10396314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-103963142023-08-03 Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies Ail, Divya Nava, Diane Hwang, In Pyo Brazhnikova, Elena Nouvel-Jaillard, Céline Dentel, Alexandre Joffrois, Corentin Rousseau, Lionel Dégardin, Julie Bertin, Stephane Sahel, José-Alain Goureau, Olivier Picaud, Serge Dalkara, Deniz Sci Adv Biomedicine and Life Sciences The anatomical differences between the retinas of humans and most animal models pose a challenge for testing novel therapies. Nonhuman primate (NHP) retina is anatomically closest to the human retina. However, there is a lack of relevant NHP models of retinal degeneration (RD) suitable for preclinical studies. To address this unmet need, we generated three distinct inducible cynomolgus macaque models of RD. We developed two genetically targeted strategies using optogenetics and CRISPR-Cas9 to ablate rods and mimic rod-cone dystrophy. In addition, we created an acute model by physical separation of the photoreceptors and retinal pigment epithelium using a polymer patch. Among the three models, the CRISPR-Cas9–based approach was the most advantageous model in view of recapitulating disease-specific features and its ease of implementation. The acute model, however, resulted in the fastest degeneration, making it the most relevant model for testing end-stage vision restoration therapies such as stem cell transplantation. American Association for the Advancement of Science 2023-08-02 /pmc/articles/PMC10396314/ /pubmed/37531424 http://dx.doi.org/10.1126/sciadv.adg8163 Text en Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Biomedicine and Life Sciences Ail, Divya Nava, Diane Hwang, In Pyo Brazhnikova, Elena Nouvel-Jaillard, Céline Dentel, Alexandre Joffrois, Corentin Rousseau, Lionel Dégardin, Julie Bertin, Stephane Sahel, José-Alain Goureau, Olivier Picaud, Serge Dalkara, Deniz Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies |
title | Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies |
title_full | Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies |
title_fullStr | Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies |
title_full_unstemmed | Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies |
title_short | Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies |
title_sort | inducible nonhuman primate models of retinal degeneration for testing end-stage therapies |
topic | Biomedicine and Life Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396314/ https://www.ncbi.nlm.nih.gov/pubmed/37531424 http://dx.doi.org/10.1126/sciadv.adg8163 |
work_keys_str_mv | AT aildivya induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies AT navadiane induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies AT hwanginpyo induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies AT brazhnikovaelena induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies AT nouveljaillardceline induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies AT dentelalexandre induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies AT joffroiscorentin induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies AT rousseaulionel induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies AT degardinjulie induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies AT bertinstephane induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies AT saheljosealain induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies AT goureauolivier induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies AT picaudserge induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies AT dalkaradeniz induciblenonhumanprimatemodelsofretinaldegenerationfortestingendstagetherapies |